Literature DB >> 18721229

A study of proliferative markers and tumor suppressor gene proteins in different grades of ependymomas.

Mehar C Sharma1, Nihar Ghara, Deepali Jain, Chitra Sarkar, Manmohan Singh, Veer S Mehta.   

Abstract

Ependymomas are CNS tumors that originate from the spinal canal and walls of the ventricular system. Considerable controversy continues to exist with regard to their prognostic factors; age and extent of resection are the only statistically significant prognostic factors yet identified. The authors report a retrospective study of a homogenous population of 119 patients harbouring ependymomas between 1991 and 2002. All clinico-radiological and follow-up data were analyzed and a pathologic review was performed by two pathologists. Immunohistochemical staining for MIB-1, Topo IIalpha, p53 and MDM2 was performed. Histopathologic grades show relationship with MIB1 and Topo IIalpha labelling indices and cut-off values of 5% can differentiate between anaplastic and lower grades. p53 and MDM2 proteins expression are not common in ependymomas; however, they are seen in higher grades only and may be involved in the tumor progression.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18721229     DOI: 10.1111/j.1440-1789.2008.00962.x

Source DB:  PubMed          Journal:  Neuropathology        ISSN: 0919-6544            Impact factor:   1.906


  2 in total

1.  C11orf95-RELA fusions and upregulated NF-KB signalling characterise a subset of aggressive supratentorial ependymomas that express L1CAM and nestin.

Authors:  Prit Benny Malgulwar; Aruna Nambirajan; Pankaj Pathak; Mohammed Faruq; Madhu Rajeshwari; Manmohan Singh; Vaishali Suri; Chitra Sarkar; Mehar Chand Sharma
Journal:  J Neurooncol       Date:  2018-01-22       Impact factor: 4.130

2.  A Nonenhancing World Health Organization Grade II Intramedullary Spinal Ependymoma in the Conus: Case Illustration and Review of Imaging Characteristics.

Authors:  Andrew A Fanous; Gregory F Jost; Meic H Schmidt
Journal:  Global Spine J       Date:  2012-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.